Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of...
- Mechanism
- Curator reviewed
Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).
- Primary indication
- Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.Curator reviewed
- Code names
- AMG-412
Resolves to
What you can answer from here — as of May 03, 2022
Which drugs share a target with Epratuzumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account